Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ENTA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With… NCT07908381 · RSV zelicapavir, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 2/3 | Recruiting | 860 | Jul 2029 | Registry ↗ |
| Aug 19, 2026 | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. NCT05568706 · RSV Infection EDP-938, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Completed | 187 | Jun 23, 2025 | Registry ↗ |
| Jul 20, 2026 | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days… NCT07482657 · RSV Infection, RSV zelicapavir, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Recruiting | 150 | Dec 2026 | Registry ↗ |
| Apr 21, 2026 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single a… NCT07540910 · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria EDP-978, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Recruiting | 98 | Nov 2026 | Registry ↗ |
| Oct 7, 2025 | A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus… NCT06170242 · RSV Infection EDP-323 Dose Regimen 1, EDP-323 Dose Regimen 2 | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Completed | 142 | Jun 17, 2024 | Registry ↗ |
| Jul 28, 2025 | A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults NCT06601192 · RSV Infection, QTc Interval zelicapavir (therapeutic dose), zelicapavir (supratherapeut… | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 72 | Feb 2, 2025 | Registry ↗ |
| Jul 28, 2025 | A Study to Evaluate EDP 938 Regimens in Children With RSV NCT04816721 · Respiratory Syncytial Virus (RSV) EDP-938, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Completed | 99 | Aug 19, 2024 | Registry ↗ |
| Jul 1, 2025 | A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin… NCT06917508 · RSV Infection, Drug Drug Interaction EDP-323, Midazolam | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 24 | Jun 6, 2025 | Registry ↗ |
| Jul 1, 2025 | A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and… NCT06847464 · RSV Infection, Drug Drug Interaction (DDI) EDP-323, Itraconazole | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 48 | May 24, 2025 | Registry ↗ |
| Aug 22, 2024 | Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial… NCT04633187 · Respiratory Syncytial Virus Infections EDP-938, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Terminated | 9 | May 31, 2023 | Registry ↗ |
| Aug 19, 2024 | A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 NCT05616728 · COVID-19 EDP-235, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Completed | 231 | Feb 8, 2023 | Registry ↗ |
| Oct 30, 2023 | A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respira… NCT04196101 · Respiratory Syncytial Virus EDP-938, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Completed | 82 | Jan 4, 2022 | Registry ↗ |
| Sep 1, 2023 | A Study of EDP-323 in Healthy Subjects NCT05587478 · RSV Infection EDP-323, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 82 | Mar 29, 2023 | Registry ↗ |
| May 19, 2023 | A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Live… NCT04378010 · Non-Alcoholic Steatohepatitis EDP-305 1.5 mg, EDP-305 2 mg | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Terminated | 98 | Oct 4, 2021 | Registry ↗ |
| Apr 27, 2023 | Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjec… NCT05594615 · COVID-19 EDP-235, Midazolam | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 24 | Nov 4, 2022 | Registry ↗ |
| Apr 27, 2023 | Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy S… NCT05594602 · COVID-19 EDP-235, EDP-235 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 36 | Dec 14, 2022 | Registry ↗ |
| Aug 19, 2022 | A Study of EDP-235 in Healthy Subjects NCT05246878 · SARS CoV 2 Infection EDP-235, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 72 | Jul 20, 2022 | Registry ↗ |
| May 3, 2022 | A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model NCT03691623 · RSV Infection EDP-938 Dose 1, EDP-938 Dose 2 | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Completed | 179 | Sep 30, 2019 | Registry ↗ |
| Mar 23, 2022 | Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects NCT04927793 · Respiratory Syncytial Virus (RSV) EDP-938 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 8 | Jul 4, 2021 | Registry ↗ |
| Feb 14, 2022 | A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PA… NCT04971512 · Chronic Hepatitis B Virus Infection EDP-721, Placebo (Part 1) | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Terminated | 26 | Dec 20, 2021 | Registry ↗ |
| Jan 11, 2022 | A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Tr… NCT04470388 · Chronic HBV Infection EDP-514, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 25 | Aug 30, 2021 | Registry ↗ |
| Jan 11, 2022 | A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infecti… NCT04008004 · Chronic HBV Infection EDP-514, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 99 | Jul 14, 2021 | Registry ↗ |
| Oct 29, 2021 | A Study of EDP-297 in Healthy Subjects NCT04559126 · NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis EDP-297, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 82 | Jun 21, 2021 | Registry ↗ |
| Oct 13, 2021 | Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in… NCT04498741 · RSV Infection EDP-938, EDP-938 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 89 | May 27, 2021 | Registry ↗ |
| Sep 16, 2021 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects Wi… NCT03421431 · Non-Alcoholic Steatohepatitis EDP-305 Dose 1, EDP-305 Dose 2 | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Completed | 134 | Jun 14, 2019 | Registry ↗ |
| Aug 16, 2021 | Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy… NCT04783753 · Hepatitis B EDP-514, EDP-514 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 72 | Jun 28, 2021 | Registry ↗ |
| May 18, 2021 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects Wi… NCT03394924 · Primary Biliary Cholangitis EDP-305 1 mg, EDP-305 2.5 mg | ENTA Enanta Pharmaceuticals, Inc | Phase 2 | Completed | 68 | Dec 19, 2019 | Registry ↗ |
| May 4, 2021 | Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects NCT04871724 · RSV Infection EDP-938, Fluconazole | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 24 | Mar 30, 2021 | Registry ↗ |
| Jul 24, 2019 | A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of… NCT03783897 · NASH - Nonalcoholic Steatohepatitis EDP-305, Oral Contraceptive | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 43 | Jun 4, 2019 | Registry ↗ |
| Jun 14, 2019 | Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subje… NCT03755778 · RSV Infection EDP-938, EDP-938 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 72 | Jan 21, 2019 | Registry ↗ |
| Feb 12, 2019 | Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects NCT03750383 · RSV Infection EDP-938, EDP-938 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 48 | Nov 17, 2018 | Registry ↗ |
| Dec 5, 2018 | Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers NCT03610945 · NASH - Nonalcoholic Steatohepatitis Fluconazole, Quinidine | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 48 | Aug 15, 2018 | Registry ↗ |
| Nov 21, 2018 | Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects NCT03748628 · NASH - Nonalcoholic Steatohepatitis EDP-305 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 8 | Oct 13, 2018 | Registry ↗ |
| Oct 10, 2018 | A Study of EDP-938 in Healthy Subjects NCT03384823 · RSV Infection EDP-938, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 90 | Jul 3, 2018 | Registry ↗ |
| Nov 6, 2017 | Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers NCT03213145 · NASH - Nonalcoholic Steatohepatitis intraconazole, Rifampin | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 48 | Aug 10, 2017 | Registry ↗ |
| Nov 6, 2017 | A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healt… NCT03207425 · NASH EDP 305 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 29 | Sep 16, 2017 | Registry ↗ |
| Aug 21, 2017 | Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunt… NCT03187496 · NASH Midazolam, Caffeine | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 24 | Jun 1, 2017 | Registry ↗ |
| Aug 21, 2017 | A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD NCT02918929 · Presumptive NAFLD EDP 305, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 146 | Jun 2017 | Registry ↗ |
| Jan 23, 2017 | EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients NCT02652377 · Hepatitis C EDP-494, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 100 | Dec 27, 2016 | Registry ↗ |
| Jan 29, 2016 | Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects NCT01856426 · Hepatitis C EDP239, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 28 | Nov 2014 | Registry ↗ |
| May 12, 2015 | Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788 NCT02255968 · Healthy EDP-788, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Terminated | 16 | Oct 2014 | Registry ↗ |
| Jan 9, 2015 | Two-way Interaction Between Alisporivir and EDP239 NCT02173574 · Hepatitis C Virus DEB025, EDP239 | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 42 | Nov 2014 | Registry ↗ |
| Jan 9, 2015 | Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788 NCT01999725 · Safety in Normal Volunteers EDP-788, Placebo | ENTA Enanta Pharmaceuticals, Inc | Phase 1 | Completed | 80 | Sep 2014 | Registry ↗ |
43 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:59 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances